Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

988 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: quinn k. Breast Cancer Res. 2024 May 24;26(1):83. doi: 10.1186/s13058-024-01833-6. Breast Cancer Res. 2024. PMID: 38790033 Free PMC article. No abstract available.
Plasma versus tissue tumor mutational burden as biomarkers of durvalumab plus tremelimumab response in patients with metastatic colorectal cancer in the CO.26 trial.
Loree JM, Titmuss E, Topham JT, Kennecke HF, Feilotter H, Virk S, Lee YS, Banks K, Quinn K, Karsan A, Renouf DJ, Jonker DJ, Tu D, O'Callaghan CJ, Chen EX. Loree JM, et al. Among authors: quinn k. Clin Cancer Res. 2024 May 10. doi: 10.1158/1078-0432.CCR-24-0268. Online ahead of print. Clin Cancer Res. 2024. PMID: 38727700
Highlight of 2023: Virtues and vices of CD4 CAR T cells.
Chinni SS, Taylor MF, Borger JG, Quinn KM. Chinni SS, et al. Among authors: quinn km. Immunol Cell Biol. 2024 Apr 24. doi: 10.1111/imcb.12764. Online ahead of print. Immunol Cell Biol. 2024. PMID: 38659345
NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
Jacobs SA, Wang Y, Abraham J, Feng H, Montero AJ, Lipchik C, Finnigan M, Jankowitz RC, Salkeni MA, Maley SK, Puhalla SL, Piette F, Quinn K, Chang K, Nagy RJ, Allegra CJ, Vehec K, Wolmark N, Lucas PC, Srinivasan A, Pogue-Geile KL. Jacobs SA, et al. Among authors: quinn k. Breast Cancer Res. 2024 Apr 22;26(1):69. doi: 10.1186/s13058-024-01823-8. Breast Cancer Res. 2024. PMID: 38650031 Free PMC article. Clinical Trial.
988 results